Allogene Therapeutics : J.P. Morgan Conference Presentation - January 2021
January 15, 2021 at 12:42 pm EST
Share
The Next Revolution in Cell Therapy
Leading Today, Creating Tomorrow
39th Annual J.P. Morgan Healthcare Conference
January 2021
Legal Disclaimers
To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this Presentation include, but are not limited to, statements regarding: clinical outcomes, which may materially change as patient enrollment continues and more patient data become available, the timing and ability to progress the clinical trials of ALLO-501,ALLO-501A and ALLO-715, the timing and ability to initiate a clinical trial of ALLO-715 in combination with SpringWorks' nirogacestat and a clinical trial of ALLO-316, the timing and ability to file an IND and initiate a clinical trial of ALLO-605, the ability to manufacture AlloCAR T™ therapies for use in clinical trials, and the potential benefits of AlloCAR T™ therapy. Various factors may cause differences between Allogene's expectations and actual results as discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended September 30, 2020.
Caution should be exercised when interpreting results from separate trials involving separate product candidates. There are differences in the clinical trial design, patient populations, and the product candidates themselves, and the results from the clinical trials of autologous products may have no interpretative value on our existing or future results.
Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2
The Allogene Vision
Create and lead the next revolution in cancer treatment by delivering to patients the first AlloCAR T™ therapies for blood cancers and solid tumors.
3
Allogene: Singular Focus on Allogeneic Cell Therapy
SUCCESSFUL TRACK RECORD OF EXECUTION
2018
Manufacturing
Clinical Trial
Breaking Down
Demonstrating
Pipeline
Allogene
Experience
Execution
Allogeneic
Efficacy
Progress
2021
Launch
Hurdles
From launch to
Delivered
Leading the field
Controlling Graft
Complete Responses
5 clinical trials planned
leadership in less
uninterrupted
with 75+ patients
vs Host Disease
and Minimal Residual
in 2021, including:
than 3 years
supply for all
treated with
(GvHD) and
Disease (MRD)
1st pivotal trial
clinical trials
AlloCAR T
AlloCAR T cell
responses observed
Raised $1.5B in
rejection
1st solid tumor trial
aggregate capital
Newark facility on
2 key Phase 1
Proof-of-Concept for
1st combo trial
track to begin
datasets presented
Creating a
proprietary
1st TurboCAR trial
production in 2021
in 2020 at major
window of cell
lymphodepletion
medical meetings
persistence
platform
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Allogene Therapeutics Inc. published this content on 15 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 January 2021 17:41:02 UTC
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.